New drug combination for newly diagnosed KMT2A leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a three-drug combination (revumenib, azacitidine, and venetoclax) for patients with a newly diagnosed type of acute myeloid leukemia (AML) that has a specific genetic change called KMT2A rearrangement. The goal is to see if this combination can help treat this type of leukemia more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML (blood cancer) that has not been treated yet
- Your leukemia has a KMT2A genetic change, confirmed by your doctor's testing
- You are between 18 and 65 years old
- You do not have leukemia cells in your brain or spinal fluid (unless previously treated and now in remission)
- You are not pregnant or breastfeeding, and willing to use birth control if needed
- You can follow study procedures and visits as required
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Leukemia Acute Myeloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.